The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1)
Receptor Agonists as of August 2014 provides a competitor analysis in
the development pipeline of novel GLP-1 analogs and GLP-1 receptor
agonists and co-agonists for treatment of diabetes and obesity.

In the year 2013, the marketed daily and weekly GLP-1 agonists achieved
combined sales of US$ 3,231 mln representing 6.3% of the total diabetes
care market. The leading GLP-1 analog Victoza held 69% of the GLP-1
market and is further expanding its predominance in the first half of
2014 with a 72% share of the GLP-1 market which grew to 6.9% of the
total diabetes care market.

The increasingly attractive GLP-1 market provides an opportunity of
application of new technologies to prolong the half-life of GLP-1
analogs as well as finding co-agonists of GLP-1 receptor with additional
receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In
addition, expansion of indications for GLP-1 analogs will contribute to
further expand the GLP-1 market.

The report provides a compilation of current active projects in research
and development of novel GLP-1 analogs and GLP-1 receptor agonists as
well as co-agonists.